Related Experiment Video
Updated: Jul 29, 2025
Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
Secreted endogenous macrosomes reduce Aβ burden and ameliorate Alzheimer's disease
Cunli Wang1,2, Yiming Yang1, Xiaoyu Zhang2
1School of Biomedical Engineering, Liaoning Key Lab of Integrated Circuit and Biomedical Electronic System, Dalian University of Technology, Lingshui Road, Dalian 116024, P. R. China.
Abstract:
Innovative therapeutic strategies are urgently needed for Alzheimer's disease (AD) due to the increasing size of the aging population and the lack of effective drug treatment. Here, we report the therapeutic effects of extracellular vesicles (EVs) secreted by microglia, including macrosomes and small EVs, on AD-associated pathology. Macrosomes strongly inhibited β-amyloid (Aβ) aggregation and rescued cells from Aβ misfolding-induced cytotoxicity. Furthermore, macrosome administration reduced Aβ plaques and ameliorated cognitive impairment in mice with AD. In contrast, small EVs slightly promoted Aβ aggregation and did not improve AD pathology. Proteomic analysis of small EVs and macrosomes revealed that macrosomes harbor several important neuroprotective proteins that inhibit Aβ misfolding. In particular, the small integral membrane protein 10-like protein 2B in macrosomes has been shown to inhibit Aβ aggregation. Our observations provide an alternative therapeutic strategy for the treatment of AD over conventional ineffective drug treatments.
Insights
Microglia-secreted macrosomes show therapeutic potential for Alzheimer's disease (AD) by inhibiting amyloid-beta (Aβ) aggregation and improving cognitive function in AD mice. Small extracellular vesicles (EVs) did not show similar benefits.
Area of Science:
- Neuroscience
- Cell Biology
- Biochemistry
Background:
- Alzheimer's disease (AD) presents a significant challenge due to an aging population and limited effective treatments.
- Innovative therapeutic strategies are crucial for managing AD-associated pathology.
Purpose of the Study:
- To investigate the therapeutic effects of extracellular vesicles (EVs) secreted by microglia on Alzheimer's disease (AD) pathology.
- To compare the efficacy of macrosomes and small EVs derived from microglia in treating AD.
Main Methods:
- Investigated therapeutic effects of microglia-derived macrosomes and small EVs on AD pathology.
- Assessed inhibition of beta-amyloid (Aβ) aggregation and cytotoxicity.
- Administered macrosomes to AD mice to evaluate plaque reduction and cognitive improvement.
- Performed proteomic analysis to identify key proteins in macrosomes and small EVs.
Main Results:
- Macrosomes significantly inhibited Aβ aggregation and rescued cells from Aβ-induced cytotoxicity.
- Macrosome administration in AD mice reduced Aβ plaques and ameliorated cognitive impairment.
- Small EVs showed minimal effect on Aβ aggregation and did not improve AD pathology.
- Proteomic analysis revealed neuroprotective proteins in macrosomes, including small integral membrane protein 10-like protein 2B, which inhibits Aβ aggregation.
Conclusions:
- Macrosomes represent a promising therapeutic strategy for Alzheimer's disease.
- Microglia-derived macrosomes offer a potential alternative to conventional AD treatments.
- Specific proteins within macrosomes, like small integral membrane protein 10-like protein 2B, are key to their neuroprotective effects.
Related Concept Videos
01:26Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
01:22Alzheimer's Disease: Treatment